These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21652733)

  • 21. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
    Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
    Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro.
    Kawata E; Ashihara E; Nakagawa Y; Kiuchi T; Ogura M; Yao H; Sakai K; Tanaka R; Nagao R; Yokota A; Takeuchi M; Kimura S; Hirai H; Maekawa T
    Cancer Lett; 2010 Aug; 294(2):245-53. PubMed ID: 20206440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549].
    Zhou Q; Bai M; Su Y
    Ai Zheng; 2005 Feb; 24(2):149-54. PubMed ID: 15694023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
    Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
    Leong CT; Ong CK; Tay SK; Huynh H
    Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
    Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
    Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
    Liu L; Zhang M; Zou P; Tian L; Liu F
    Ai Zheng; 2006 Apr; 25(4):404-8. PubMed ID: 16613670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer.
    Edling CE; Selvaggi F; Buus R; Maffucci T; Di Sebastiano P; Friess H; Innocenti P; Kocher HM; Falasca M
    Clin Cancer Res; 2010 Oct; 16(20):4928-37. PubMed ID: 20876794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.
    Markant SL; Esparza LA; Sun J; Barton KL; McCoig LM; Grant GA; Crawford JR; Levy ML; Northcott PA; Shih D; Remke M; Taylor MD; Wechsler-Reya RJ
    Cancer Res; 2013 Oct; 73(20):6310-22. PubMed ID: 24067506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma.
    Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M
    Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
    Wang G; Rong J; Zhou Z; Duo J
    Mol Biol (Mosk); 2010; 44(6):1010-7. PubMed ID: 21287809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
    Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
    Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1.
    Li KK; Pang JC; Ching AK; Wong CK; Kong X; Wang Y; Zhou L; Chen Z; Ng HK
    Hum Pathol; 2009 Sep; 40(9):1234-43. PubMed ID: 19427019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
    Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
    J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MPS1 kinase as a potential therapeutic target in medulloblastoma.
    Alimova I; Ng J; Harris P; Birks D; Donson A; Taylor MD; Foreman NK; Venkataraman S; Vibhakar R
    Oncol Rep; 2016 Nov; 36(5):2633-2640. PubMed ID: 27633003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
    Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
    Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.